Replies to post #1045 on Bionanao Genomics Inc (BNGO)

[BottomBounce]

$BNGO Preliminary Data Confirm Saphyr’s Potential to Replace Traditional Cytogenetics Methods for Detection of Structural Variants in Certain Blood Cancers. Strong concordance with standard of care methods shows how Saphyr can transform cytogenetic workflows and provide an approach that may be faster and more cost-effective and may give better results
https://www.globenewswire.com/news-release/2019/08/13/1901025/0/en/Preliminary-Data-Confirm-Saphyr-s-Potential-to-Replace-Traditional-Cytogenetics-Methods-for-Detection-of-Structural-Variants-in-Certain-Blood-Cancers.html

[BottomBounce]

$BNGO Professors from George Washington University and Children’s National Medical Center presented a number of cases from the Undiagnosed Diseases Network, patients with Disorders of Sex Development, Gitelman’s Syndrome, FSHD and Beckwith-Wiedeman syndrome where Bionano was able to provide a molecular diagnosis, identify new likely causative genes, or identify structural variants affecting known or expected disease genes. http://www.globenewswire.com/news-release/2019/10/24/1934941/0/en/Takeaways-from-ASHG-2019-in-Houston-Users-of-Bionano-s-Saphyr-System-Presented-Validation-Results-for-FSHD-Repeat-Expansion-Disorders-and-Digital-Cytogenetics-Among-a-Growing-List-.html